India Pharmaceutical Market Reflection Report Mar 2015

0

Market Reflection Report March 2015

1

IPM overview


TSA IPM Trends SSA IPM Trends

IPM was valued at Rs. 90,346 crs and the retail sector was valued at Rs. 76,482 crs as of MAT Mar’15 with CAGR growth of 11%

during the period 2012-15

Anti-infectives, Cardiac and Gastro Intestinal remains the leading therapeutic categories accounting for 36% of IPM

Indian companies continue to drive growth in the market with Sun catapulted to the top of the league, after its merger deal with

Ranbaxy fructified, as forecasted by IMS Health in Jan ‘15

Acute therapies dominates the market constituting 70% of IPM

Mo

nth

Gro

wth

%

Value Rs. crs

Growth SPLY

90,346

80,566

73,096

66,054

7,4646,4145,8615,446

+16%

+12%

2015 2014 2013 2012

76,482

67,709

61,394

55,577

6,2815,3954,8844,551

+16%

+13%

2015 2014 2013 2012

Month MAT

20

15

10

5

0

25

Dec Nov Oct Sep Aug Jul Jun May Apr Mar Feb Jan

25

20

0

10

5

15

Dec Nov Oct Sep Aug Jul Jun May Apr Mar Feb Jan

2013

2015

2014

2

Top 150 companies snapshot

• Lupin moved up among the top 10 companies as a result of the merger of Ranbaxy with Sun; the market share of

the top 10 companies increased from 40% of IPM in Feb ’15 to 43% in Mar ’15 on MAT and month basis

• The top 150 companies continue to account for 97% of IPM on MAT and month basis

Source: IMS Health TSA, Mar ‘15

IPM value – Rs.7,464 crs (16% Growth)

Month Mar ‘15 IPM value – Rs.90,346 crs (12% Growth)

MAT Mar ‘15

249

494

488

381

830

Value (Rs. Crs)

Rank #101 - 150

Rank #61 - 100

Rank #41 - 60

Rank #31 - 40

Rank #21 - 30

Rank #11 - 20 1,623

Rank #1 - 10 3,193

3

7

7

5

11

22

43

% MS

9

14

18

14

18

21

15

% Gwth Value (Rs. Crs)

3,087

6,029

5,901

4,762

9,976

19,244

38,851

3

7

7

5

11

21

43

% MS

8

12

18

12

11

13

12

% Gwth


3

Top companies #1-10

TSA: Macleods registered significant growth greater than 20% both on MAT and month basis.

SSA: Intas registered double the growth % of IPM during the month while Macleods and Mankind registered

significant growth greater than 20% both on MAT and month basis Source: IMS Health TSA & SSA, Mar ‘15

250

254

261

269

382

470

618

Value

(Rs. Crs)

Lupin Limited 214

Pfizer 226

Macleods Pharma 248

Alkem

GlaxoSmithKline

Zydus Cadila

Mankind

Cipla

Abbott

Sun

17

11

26

19

10

7

24

19

12

11

% Gwth

2.9

3.0

3.3

3.4

3.4

3.5

3.6

5.1

6.3

8.3

% MS

179

181

204

217

218

220

240

302

401

524

Value

(Rs. Crs)

Intas Pharma

Lupin Limited

GlaxoSmithKline

Macleods Pharma

Zydus Cadila

Alkem

Mankind

Cipla

Abbott

Sun

32

18

11

27

8

21

24

18

11

12

% Gwth

2.8

2.9

3.3

3.5

3.5

3.5

3.8

4.8

6.4

8.3

% MS

Mo

nth

Value

(Rs. Crs)

Lupin Limited 2,581

Pfizer 2,745

Macleods Pharma 2,933

GlaxoSmithKline 3,088

Alkem 3,113

Mankind 3,171

Zydus Cadila 3,181

Cipla 4,760

Abbott 5,742

Sun 7,538

15

9

23

5

11

19

3

20

8

10

% Gwth

2.9

3.0

3.3

3.4

3.5

3.5

3.5

5.3

6.4

8.3

% MS

Value

(Rs. Crs)

Lupin Limited 2,173

Pfizer 2,218

GlaxoSmithKline 2,523

Macleods Pharma 2,556

Zydus Cadila 2,667

Alkem 2,717

Mankind 2,825

Cipla 3,777

Abbott 4,974

Sun 6,398

16

8

8

25

4

12

20

16

8

11

% Gwth

2.8

2.9

3.3

3.3

3.5

3.6

3.7

4.9

6.5

8.4

% MS

MA

T

SS

A T

SA


4

Top companies #11-20

• TSA –The majority of companies in this bucket posted significant growth greater 20% than during the month

• SSA –Similarly, Dr. Reddys, Aristo, Torrent and Alembic posted strong retail growth greater than 20% during the

month Source: IMS Health TSA & SSA, Mar ‘15

149

167

169

175

176

182

209

Value

(Rs. Crs)

Micro Labs 122

Alembic 125

Glenmark Pharma 147

U S V

Sanofi

Emcure

Dr Reddys Labs

Aristo Pharma

Torrent Pharma

Intas Pharma

12

24

20

14

16

8

28

28

24

33

% Gwth

1.6

1.7

2.0

2.0

2.2

2.3

2.4

2.4

2.4

2.8

% MS

104

113

123

128

135

144

146

156

160

177

Value

(Rs. Crs)

Micro Labs

Alembic

Sanofi

Glenmark Pharma

U S V

Emcure

Dr Reddys Labs

Aristo Pharma

Torrent Pharma

Pfizer

15

24

10

19

15

9

30

28

25

9

% Gwth

1.7

1.8

2.0

2.0

2.2

2.3

2.3

2.5

2.6

2.8

% MS

Value

(Rs. Crs)

Alembic 1,494

Micro Labs 1,517

U S V 1,746

Glenmark Pharma 1,781

Dr Reddys Labs 1,949

Aristo Pharma 2,019

Sanofi 2,061

Emcure 2,126

Torrent Pharma 2,170

Intas Pharma 2,381

14

7

9

19

13

15

5

12

11

21

% Gwth

1.7

1.7

1.9

2.0

2.2

2.2

2.3

2.4

2.4

2.6

% MS

Value

(Rs. Crs)

Micro Labs 1,284

Alembic 1,354

Sanofi 1,544

Glenmark Pharma 1,551

U S V 1,577

Dr Reddys Labs 1,651

Emcure 1,777

Aristo Pharma 1,796

Torrent Pharma 1,902

Intas Pharma 2,037

9

15

11

19

10

17

13

16

12

21

% Gwth

1.7

1.8

2.0

2.0

2.1

2.2

2.3

2.4

2.5

2.7

% MS

SS

A T

SA

Mo

nth

M

AT


5

Top companies #21-30

• TSA – Wockhardt and Ipca registered double the IPM growth during the month

• SSA –Wockhardt, Ipca, Indoco and Cadila registered significant growth of 20% during the month

Source: IMS Health TSA & SSA, Mar ‘15

70

78

79

91

106

109

121

55

61

61

Value

(Rs. Crs)

Indoco

Franco Indian

Merck Limited

Cadila Pharma

MSD Pharma

Unichem

FDC

Novartis Intl.

Ipca Labs

Wockhardt Ltd

20

12

8

28

9

11

15

6

32

37

% Gwth

0.7

0.8

0.8

0.9

1.0

1.1

1.2

1.4

1.5

1.6

% MS

49

54

57

58

60

72

84

93

96

99

Value

(Rs. Crs)

Indoco

Merck Limited

Franco Indian

Cadila Pharma

MSD Pharma

Unichem

FDC

Novartis Intl.

Ipca Labs

Wockhardt Ltd

21

11

11

25

7

12

16

6

35

27

% Gwth

0.8

0.9

0.9

0.9

1.0

1.1

1.3

1.5

1.5

1.6

% MS

668

733

777

850

959

Value

(Rs. Crs)

Indoco

Franco Indian

Merck Limited

Cadila Pharma

MSD Pharma

Unichem 1,006

FDC 1,060

Wockhardt Ltd 1,284

Ipca Labs 1,303

Novartis Intl. 1,336

11

10

9

15

8

8

8

14

20

3

% Gwth

0.7

0.8

0.9

0.9

1.1

1.1

1.2

1.4

1.4

1.5

% MS

604

686

689

724

757

913

982

Value

(Rs. Crs)

Indoco

Merck Limited

Franco Indian

Cadila Pharma

MSD Pharma

Unichem

FDC

Wockhardt Ltd 1,101

Ipca Labs 1,139

Novartis Intl. 1,164

12

10

10

15

9

8

8

10

22

3

% Gwth

0.8

0.9

0.9

1.0

1.0

1.2

1.3

1.4

1.5

1.5

% MS

SS

A T

SA

Mo

nth

M

AT

6

Highlights

TSA

Movers & Shakers TSA: Companies

In the month of March’15(in comparison to

Feb’15), among the top 25 companies

Sun Pharma has moved 2 ranks to achieve top

position in the IPM with market share of 8.28 %.

Aristo Pharma has gained 4 ranks and moved to

13th position.

Glaxosmithkline has gained 3 ranks and moved

to 6th position.

Dr Reddys Labs & USV have gained 2 ranks

and moved to 14th & 17th position respectively.

As per March’15 MAT (in comparison to

Feb’15) among the top 25 companies



Companies below Ranbaxy have gained 1 rank

post Sun-Ranbaxy merger.

SSA

Movers & Shakers SSA: Companies

In the month of March-15 (in comparison to

February-15 month), among the TOP 25

companies



Alkem & Lupin have gained 3 ranks each &

occupied 5th & 9th position respectively.

Dr Reddys Labs & USV have gained 2 ranks

each & occupied 14th & 16th position

respectively.

Intas gained 1 rank to occupy the 10th position

As per March-15 MAT (in comparison to

February-15 MAT), among the TOP 25

companies



Aristo Pharma & Glenmark have gained 2 ranks

each & occupied 13th & 17th position

respectively.


7

NLEM/Non-NLEM

Valu

e

Vo

lum

e

NLEM impacted drugs constituted 15% of IPM in value terms with a growth of 10.4% as of MAT Mar ‘15 over same

period last year (SPLY)

The share of the non-NLEM drugs was 76% of IPM in volume terms for the month of Mar’15


SPLY Previous month

Mar '14 Mar '15 Value Growth

(%)

Feb '15 Mar '15 Value Growth (%)

Rs. (crs) Rs. (crs) Rs. (crs) Rs. (crs)

NLEM 989.1 1091.9 10.4 1119.2 1091.9 -2.4

Non-NLEM 5424.5 6371.7 17.5 6439.7 6371.7 -1.1

IPM 6413.6 7463.6 16.4 7558.8 7463.6 -1.3

SPLY Previous month

Mar '14 Mar '15 Volume Growth

(% )

Feb '15 Mar '15 Volume Growth

(%) Units (‘000) Units (‘000) Units (‘000) Units (‘000)

NLEM 380800 399972 5.0 406526 399972 -1.6

Non-NLEM 1184052 1298946 9.7 1322253 1298946 -1.8

IPM 1564851 1698918 8.6 1728779 1698918 -1.7


8

Indian /MNC trends

• Indian companies continue to capture the larger share of IPM at 74% during the month with a significant growth of

18.6% over Mar’14

• MNCs registered a growth of 10.4% as against the IPM growth of 16.4% during the month


0

5

10

15

20

25

Apr ’14

IPM

Mar ’15 Feb ’15 Jan ’15 Dec ’14 Nov ’14 Oct ’14 Sep ’14

% Gwth over same month last year

Jun ’14 May ’14 Jul ’14 Aug ’14

MNC

Indian

0

1,000

2,000

3,000

4,000

5,000

6,000

7,000

8,000

Value (Rs. Crs)

MNC

Apr ’14 Jul ’14 Aug ’14 Sep ’14 Oct ’14 Nov ’14 Dec ’14 Jan ’15 Mar ’15 Feb ’15

Indian

IPM

Jun ’14 May ’14

Mo

nth

Gro

wth

V

alu

e


9

Acute/Chronic trends

Acute therapies continue to dominate the market accounting for 70% of the market during the month

Chronic therapies registered growth of 15%, while acute therapies posted growth of 17% in Mar ‘15

Cough preparation was the highest selling therapeutic subgroup in value terms with significant growth of 30% during the

month Source: IMS Health TSA, Mar ‘15

5

10

15

20

25

Apr ’14 Mar ’15 Feb ’15 Jan ’15 Dec ’14 Nov ’14 Oct ’14 Sep ’14 Aug ’14 Jul ’14 Jun ’14 May ’14

8788108118

155

Amoxy. & Clav. Solids Food Supplements Glim+Metformin DPP4 inhibitors & Comb Cough Preps Ethical

30.37 20.40 17.63 -5.05 23.03

9

16

19

Franco Indian

Wockhardt Ltd

Glenmark Pharma

19

26

27

U S V

Novartis Intl.

MSD Pharma

10

11

23

Lupin Limited

Sun

U S V

13

14

15

Nutricia Internat

Abbott

Apex

14

14

17

Mankind

Alkem

GlaxoSmithKline

To

p 5

TC

4s

T

op

3 C

os. in

TC

4

Growth (%)

Value (Rs.

Crs)

Value (Rs. Crs)

Gro

wth

(%

)

Value (Rs. Crs) Value (Rs. Crs) Value (Rs. Crs) Value (Rs. Crs)

Chronic Acute IPM


10

Top 40 brands

Abbott, Alkem and GlaxoSmithKline have the highest number of brands among the top 40 at 5 each

The vaccine Synflorix (GlaxoSmithKline) registered outstanding growth of 83% during the month

Thyronorm (Abbott), Spasmo-Proxyvon + (Wockhardt) and Shelcal (Torrent Pharma) posted impressive growth

greater than 40% in Mar ’15 over the same month last year

22

23

23

23

26

28

38

20

20

21

Value

(Rs. Crs)

Voveran (Novartis Intl.)

Phensedyl Cough (Abbott)

Clavam (Alkem)

Thyronorm (Abbott)

Glycomet-GP (U S V)

Monocef (Aristo Pharma)

Prevenar-13 (Pfizer)

Corex (Pfizer)

Augmentin (GlaxoSmithKline)

Mixtard (Abbott)

29

8

25

47

18

36

38

16

21

11

% Gwth % MS

0.26

0.27

0.28

0.29

0.30

0.31

0.31

0.35

0.38

0.51

14

15

15

15

15

15

16

16

16

17

Value

(Rs. Crs)

Pan (Alkem)

Moxikind-CV (Mankind)

Calpol (GlaxoSmithKline)

Zincovit (Apex)

Becosules (Pfizer)

Zifi (FDC)

Foracort (Cipla)

Shelcal (Torrent Pharma)

Liv-52 (Himalaya Drug)

Alburel (Reliance Lifescie.)

17

28

27

11

13

37

20

40

7

26

% Gwth % MS

0.19

0.20

0.20

0.20

0.20

0.21

0.21

0.21

0.22

0.22

17

18

18

18

18

19

19

19

19

20

Value

(Rs. Crs)

Janumet (MSD Pharma)

Betadine (Win Medicare)

Lantus (Sanofi)

Galvus Met (Novartis Intl.)

Synflorix (GlaxoSmithKline)

Novomix (Abbott)

Panderm+ (Macleods Pharma)

Spasmo-Proxyvon + (Wockhardt)

Dexorange (Franco Indian)

Volini (Sun)

20

8

7

17

83

18

37

45

4

6

% Gwth % MS

0.23

0.24

0.24

0.24

0.24

0.25

0.26

0.26

0.26

0.26

12

13

13

13

13

13

14

14

14

14

Value

(Rs. Crs)

Pan-D (Alkem)

Aciloc (Cadila Pharma)

Taxim (Alkem)

Zinetac (GlaxoSmithKline)

Eltroxin (GlaxoSmithKline)

Azithral (Alembic)

Budecort (Cipla)

Taxim-O (Alkem)

Duphaston (Abbott)

Electral (FDC)

25

13

14

0

10

30

38

18

13

18

% Gwth % MS

0.16

0.17

0.17

0.17

0.17

0.18

0.19

0.19

0.19

0.19

To

p 1

-10

To

p 1

1-2

0

To

p 2

1-3

0

To

p 3

1-4

0



11

Star Brands of the month

TSA

Movers & Shakers TSA: Products

Among the Top 25 Products as per Mar’15 MAT (in comparison to Feb’15 MAT)

Mixtard is the No 1 brand.

Thyronorm and Voveran has gained 2 ranks each to occupy 6th and 14th position respectively.

Aciloc has gained 4 ranks to occupy 25th position.

Shelcal has gained 1 rank to occupy 23rd position.

Among the Top 25 products as per March’15 month (in comparison to Feb’15 month)

Mixtard is the No 1 brand.

Synflorix has gained 24 ranks to occupy 16th position.

Spasmo-Proxyvon + has gained 6 ranks to occupy 13th position.

Dexorange and Zifi have gained 5 ranks each to occupy 12th and 25th position respectively.

Prevenar-13, Monocef & Alburel have gained 4 ranks each to occupy 4th, 5th and 21st position respectively.

Shelcal has gained 3 ranks each to occupy 23rd position.

Volini has gained 2 ranks to occupy 11th position.

Phensedyl Cough & Voveran have gained 1 rank each to occupy 9th & 10th position respectively.


12

Gastro Intestinal

1,066

IPM 7,464

774

866

535

589

591

Cardiac

Respiratory

Anti Diabetic

630

Pain / Analgesics

Anti-infectives

Vaccines 178

Others 240

Gynaec. 416

Neuro / CNS 450

Derma 456

Vitamins / Minerals / Nutrients 7

6

2

3

6

6

8

8

8

10

12

14

100

36

11

22

11

15

17

18

15

21

17

13

20

16

0

8

2

-1

-2

2

1

-1

-9

0

-1

-4

-1

Gwth % (SPLY) Gwth% (Prev. Mth)

Therapy trends

• Vaccines continues to record remarkable value growth of 36% as of MAT Mar ’15

• Anti-infectives constitute the largest market share of 14%, with significant growth on MAT basis


Value (Rs Crs) MS %


13

Top Therapy Trends


29

30

33

33

42

44

48

54

57

95

Value

(Rs. Crs)

Amikacin

Cefuroxime Oral Solids

Meropenem

Piperacillin+Tazobactam

Cefpodoxime Solids

Azithromycin Oral Solids

Amoxy. & Clav. Liquids

Cefixime Oral Sol.

Ceftriaxone Injectabls

Amoxy. & Clav. Solids

28

16

7

22

30

27

39

16

30

28

% Gwth (SPLY)

18

24

29

29

31

32

33

40

43

66

Value

(Rs. Crs)

Losartan+ Hydrochlorthiaz

Amlodipine+Telmisartan

Amlodipine

Enoxaparin

Telmisartan + Hct

Atenolol+Amlodipine

Metoprolol

Telmisartan

Rosuvastatin

Atorvastatin

5

26

9

6

11

15

12

22

23

14

% Gwth (SPLY)

An

ti-I

nfe

cti

ve

21

22

23

24

27

29

38

39

43

47

Value

(Rs. Crs)

Digest. Inc. Enzyme Liqui

Rabeprazole

Omepraz.+ Domperid.

Antacid+Antiflatu.Liq

Others

Oral Electrolytes

Pantoprazole Solids

Ranitidine Oral Solids

Rabepra.+ Domperid.

Pantopr.+ Domperid.

26

13

14

20

23

47

15

14

24

25

% Gwth (SPLY)

14

15

18

21

30

31

40

42

67

176

Value

(Rs. Crs)

Levocetirizine

Salbutamol+Ipratropium

Budesonide

Salmeterol+Fluticasone

Cold Prep. Solids

Formoteral+Budesonide

Levocetiriz.+Montelu Sold

Cold Prep. Liquids

Codeine And Comb.

Cough Prep. Ethicals

21

28

42

17

24

23

26

23

8

35

% Gwth (SPLY)

Card

iac

GI

Resp

irato

ry

• Oral Electrolytes, Budesonide, Amoxy. & Clav. Liquids and Cough Prep. Ethicals registered significant growth greater

than 34% over the same period last year


14

Glossary Abbreviation Description/Definition

IPM Indian Pharmaceutical Market

MAT Moving Annual Total

CAGR Compound Annual Growth Rate

TSA Total Sales Audit

SSA Secondary Sales Audit

Gwth Growth

MS Market Share

Rs Rupees

NLEM National List of Essential Medicines

SPLY Same Period Late Year

MNC Multi-National Company

DPP Dipeptidyl Peptidase 4

TC Therapeutic Category

Crore / crs 10 million


15

About IMS Health World’s leading provider of healthcare consulting, technology, and informatics

Founded in 1954

Operates in over 100 countries; employs 10,000+ people world wide

Data from 100,000 suppliers and insights of more than 40 billion healthcare transactions

1200+ experts resources, 3000+ service resources and 5000+ clients

Operational in India for more than 11 years, with over 2000 employees with of f ices in Gurgaon, Mumbai, Delhi & Bangalore

PUBLIC HEALTH

Policy reforms and advocacy Enabling evidence based public health

decisions

Health infrastructure development Health resources planning and

allocation Monitoring & evaluation Designing and implementation support

Strengthening health care supply chain

Enabling Technology Solutions

Product & Portfolio strategy Entry & Growth Strategy Brand and Commercial Strategy

Pricing and market access Launch and commercial Excellence

Performance management Transaction Advisory Services and

Due Diligence

Drug sales database (global and local) Census - Physicians, Chemists,

Hospitals, Doctor , etc

PHARMA & ALLIED HEALTH

Network expansion and management Doctor selection Pharma & Provider engagement

strategy Disease management

Claims database Claims analytics – benchmarks and

costs

Patient level information Health technology assessment

PAYERS PROVIDERS

Provider databases Hospital performance transformation

programs

Performance benchmarking Expansion & Growth strategy

Feasibility analysis and business plan development

Brownfield hospital acquisition

Financial modeling, funding modalities and transaction advisory

BI Solutions for hospitals

OUR SERVICE OFFERINGS

95 process patents worldwide in life sciences processes

Ranked 2nd Life Science

Technology Vendors for 2013 (IT Services) by IDC

World’s most admired companies FORTUNE Magazine

2008 and 2010

PHARMA AND LIFE-SCIENCES

16

Disclaimer

The analyses, their interpretation, and related information contained herein are made and provided subject to the assumptions, methodologies, caveats,

and variables described in this report and are based on third party sources and data reasonably believed to be reliable. No warranty is made as to the

completeness or accuracy of such third party sources or data.

IMS Health captures 90% of the retail sector and 65% of the hospital sector through individual audits, the Stockist Sell-Out Audit (SSA) and Hospital

Secondary Audit (HSA), as well as the dispensing doctors sector as part of the Total Sales Audit (TSA) from 2007 onwards. The combined audited

sectors accounted for an estimated 87.4% of the total pharmaceutical market in 2014.

As with any attempt to estimate future events, the forecasts, projections, conclusions, and other information included herein are subject to certain risks

and uncertainties, and are not to be considered guarantees of any particular outcome.

It should neither be regarded as comprehensive nor sufficient for making decisions, nor should it be used in place of professional advice. IMS Health

accepts no responsibility for any loss arising from any action taken or not taken by anyone using this material.

All reproduction rights, quotations, broadcasting, publications reserved. No part of this presentation may be reproduced or transmitted in any form or by

any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without express written consent of

IMS HEALTH.

©2015 IMS Health Incorporated and its affiliates. All rights reserved. Trademarks are registered in the United States and in various other countries.

Healthcare

India Pharmaceutical Market Reflection Report Mar 2015